Dinutuximab (ch14.18), an IgG1 human–mouse chimeric switch variant of murine mAb 14G2a was first authorized by the FDA in 2015 in combination with sargramostim a granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma with at least partial response after first-line multimodality therapy [52]. Here, CSF2 is linked to neuroblastoma.